Response to Fleshner et al., "Bridging the Gap in Acne Vulgaris Research for Skin of Color Patients: Response to: "Assessing the Inclusion of Post-Inflammatory Hyperpigmentation Outcomes in Acne Vulgaris Clinical Trials" [0.03%]
对Fleshner等关于“肤色患者寻常痤疮研究缺口”的回应："评估临床试验中将色素沉着过度结果纳入寻常痤疮临床试验"的回应
Alyssa Swearingen,Christine Olagun-Samuel,Prince Adotama
Alyssa Swearingen
Response to Kang et al.'s "Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study" [0.03%]
韩等关于“低剂量口服米诺地尔治疗乳腺癌患者抗肿瘤治疗诱发的脱发：一项回顾性队列研究”的评论回应
Caitlin A Kearney,Anna L Brinks,Carli D Needle et al.
Caitlin A Kearney et al.
Lauren Fleshner,Katie Roster,Sarah Balboul et al.
Lauren Fleshner et al.
Scott Kuan-Wen Wang,Sharon Pan,Gauri Panse et al.
Scott Kuan-Wen Wang et al.
Response to Kearney et al.'s "Response to Kang et al.'s 'Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study'" [0.03%]
Kearney等关于“Kang等关于‘低剂量口服敏乐定治疗乳腺癌患者抗肿瘤药物诱发的脱发：一项回顾性队列研究’的回复”的回复
Jeewoo Kang,Ji Won Lee,Ohsang Kwon
Jeewoo Kang
Ethical Implications of Residency Programs Researching Applicants Online [0.03%]
关于住院医师项目在线研究申请者的伦理含义
Timothy Klufas,Shannon Hanggodo,Ayushya Ajmani et al.
Timothy Klufas et al.
North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Populations [0.03%]
北美特殊人群汗腺炎临床实践指南医学管理
Raed Alhusayen,Serena Dienes,Megan Lam et al.
Raed Alhusayen et al.
Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. ...
Retrospective analysis reveals a decrease in reimbursement of pathology costs while patient out-of-pocket expense has increased [0.03%]
回顾性分析发现病理费用的报销减少了，而患者的自费部分增加了
Natella Maglakelidze,Ashwath Sampath,Allison Locy et al.
Natella Maglakelidze et al.
Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial [0.03%]
替拉珠单抗治疗中至重度头皮斑块状银屑病的疗效和安全性：来自III期、随机、双盲、安慰剂对照试验的第52周结果
Howard L Sofen,Kurt Gebauer,Lynda Spelman et al.
Howard L Sofen et al.
Background: In the primary analysis of a Phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleu...